Trial Profile
An open-label, randomized, parallel-group, multicenter study to compare the efficacy and safety of 'switching' to rosuvastatin 10 mg daily versus atorvastatin 10 mg daily with ezetimibe 10 mg daily versus doubling the dose of atorvastatin to 20 mg daily in subjects with hypercholesterolemia and atherosclerotic or coronary vascular disease or diabetes mellitus who have not achieved study target LDL-C [low density lipoprotein- cholesterol] goal while dosing with atorvastatin 10 mg daily
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Atorvastatin; Rosuvastatin
- Indications Coronary artery disease; Diabetes mellitus; Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Organon
- 31 Mar 2022 This trial has been completed in Finland (Global end date: 23 June 2005).
- 23 Apr 2008 New trial record.